HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

AbbVie has agreed to help finance a KRAS inhibitor from Kestrel Therapeutics in a deal that could hit up to $1.45 billion in value and end with AbbVie buying the company outright.

By FierceBiotech · May 1, 2026 · via FierceBiotech
AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
DealsFiercePharma ↗
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema…
May 2, 2026
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
DealsFierceBiotech ↗
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the dru…
May 1, 2026
AstraZeneca Reverses UK Freeze with £300M Restart, Merck Still Holding Out
DealsBriefing
AstraZeneca Reverses UK Freeze with £300M Restart, Merck Still Holding Out
AstraZeneca resumes its shelved £300M UK expansion after rebate relief and a U.S.-U.K. pharma pact, signaling …
May 1, 2026